医学
膀胱癌
类有机物
肿瘤科
内科学
个性化医疗
药物反应
药品
一致性
癌症
临床试验
功效
转录组
癌症研究
精密医学
药物重新定位
生物标志物
抗药性
细胞毒性
曲美替尼
液体活检
癌细胞
药理学
癌细胞系
帕纳替尼
免疫疗法
药物发现
抗癌药物
作者
Lu Junlin,Kaiwen Jie,Chu Liu,Lai Jiajian,Xu Peng,Xinxin He,Xiao Kanghua,Chen Yating,Liu Sen,Chen Zehua,Jianhui Zhang,Yang Zegeng,Lin Shizhi,Zhang Qiang,Huang Ming,Cheng Liang,Siting Chen,Jianmei Zhong,Li Sheng,Li Hong
标识
DOI:10.21147/j.issn.1000-9604.2026.05.11
摘要
Objective: Therapeutic resistance remains a major challenge in bladder cancer treatment. The aim of this study was to develop and validate a bladder cancer patient-derived organoid (PDO)-based platform for treatment response prediction and individualized salvage therapy screening. Methods: A total of 101 patients with bladder cancer were enrolled to establish 75 PDO lines. The optimal culture medium was determined by transcriptome analysis. Consistency validation was performed via histopathology, immunohistochemistry, whole-exome sequencing, and transcriptomic profiling. A three-step high-throughput screening pipeline for 288 approved agents was developed to identify salvage therapies for patients who were multidrug-resistant, which was validated in patient-derived xenograft (PDX) models. A suspension coculture system was constructed to evaluate HER2-targeted chimeric antigen receptor T (CAR-T) cell cytotoxicity and activation. Results: FGF4 supplementation significantly enhanced the 3D growth and establishment efficiency of PDOs, yielding a biobank of 75 bladder cancer PDOs. These PDOs faithfully recapitulated the multidimensional features of parental tumors, and showed preliminary concordance with observed clinical treatment responses (cisplatin, gemcitabine, and epirubicin). To address drug resistance, the high-throughput drug screening pipeline maps individualized sensitivity profiles in four cases. In a patient who was multidrug-resistant, idarubicin was pinpointed as a potent candidate agent, with efficacy confirmed in PDX models. To extend the screening platform beyond chemotherapeutics and cover cellular immunotherapies, we verified that the coculture system enabled HER2 expression-dependent CAR-T cytotoxicity evaluation. Conclusions: This integrated bladder cancer PDO platform provides a clinically relevant individualized tool for treatment response prediction and individualized salvage therapy selection, particularly for patients with multidrug-resistant disease. Its application may support tailored therapeutic decision-making across chemotherapy, targeted therapy, and cellular immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI